Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
Document text
Principal Investigator: Asrar B. Malik Organization: UNIVERSITY OF ILLINOIS AT CHICAGO Fiscal Year: 2022 Award: $739,004 Funding agency: National Heart Lung and Blood Institute PROJECT SUMMARY / ABSTRACT Coronavirus disease 2019 (COVID-19) is a devastating systemic inflammatory syndrome caused by the coronavirus SARS-CoV-2 which has resulted in over 500,000 deaths in the US during the past year, with this high rate of mortality being attributed in large part to the development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS). SARS-CoV-2 entry into cells requires the direct binding of the SARS-CoV-2 spike (S)-protein to the principal host protease-TMPRSS2 and the angiotensin converting enzyme 2 (ACE-2) receptors which are expressed in multiple host cell types. The development of efficacious vaccines to prevent the spread of SARS-CoV-2 represents a tremendous advance that will help curb the COVID-19 pandemic, however the emergence of variants of concern such as the B1.1.7, P1 and B1.351 which can evade the neutralizing responses of the vaccine-induced humoral immune response underscores the urgent need to develop novel therapeutics to complement the vaccination efforts. Based on our provocative Supporting Data, we have formulated the overarching hypothesis that SARS-CoV-2 induced lung endothelial injury is a requisite element of COVID-19 induced maladaptive inflammatory injury that can be therapeutically targeted. We propose the following specific aims: In Aim 1, we will define the nature and underlying mechanisms of lung endothelial injury underlying COVID-19-induced ALI/ARDS. We will test the hypothesis that the degree of lung endothelial injury is a key determinant of the overall pathogenicity and mortality of multiple SARS- CoV-2 variants. We will establish SARS-CoV-2-induced lung vascular injury and compensatory lung endothelial regeneration using two complementary humanized ACE2 mouse models, EC-specific genetic lineage tracing, genetic stabilization of VE-cadherin and single cell RNA-Sequencing. In Aim 2, we will define the efficacy and optimal temporal windows for two targeted pharmacological therapeutic strategies in preventing and resolving SARS-CoV- 2 induced lung endothelial injury. We will test the hypothesis that an engineered soluble hACE-2 peptide has a higher therapeutic efficacy than the wildtype hACE-2 peptide in reducing lung endothelial injury as well as long-term EC reprogramming by preventing viral entry and dissemination of multiple SARS-CoV-2 variants. We will test the corollary hypothesis and that targeted inhibition of IL1β-signaling using a modified IL-1 Receptor antagonist is protective against the feed-forward inflammatory loop and endothelial injury induced by multiple SARS-CoV2 variants. We will use two hACE-2 mouse models as well as compare distinct routes of delivery (intratracheal versus intravenous) and identify the optimal temporal windows for the therapeutic intervention. Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><7B4 Antigen><7B4 protein><ACE2><ARDS><Acute><Acute Lung Injury><Acute Pulmonary Injury><Acute Respiratory Distress><Acute Respiratory Distress Syndrome><Adherens Junction><Adhering Junction><Adhesive Junction><Adult ARDS><Adult RDS><Adult Respiratory Distress Syndrome><Affinity><Anchoring Junction><B cell differentiation factor><B cell stimulating factor 2><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><BCDF><BSF-2><BSF2><Beta Proprotein Interleukin 1><Binding><Binding Proteins><Biological Response Modifiers><Biomodulators><Blood Vessels><Body Tissues><CD144 Antigen><COVID crisis><COVID disease severity><COVID epidemic><COVID pandemic><COVID severity><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 disease severity><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 severity><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapy><COVID-19 treatment><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 crisis><COVID19 disease severity><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 severity><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Categories><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular injury><Cessation of life><CoV-2><CoV2><Complement><Complement Proteins><Complication><Coronaviridae><Coronavirus><Da Nang Lung><Data><Death><Development><Disease><Disorder><Down-Regulation><Downregulation><Dropsy><Dysfunction><Edema><Elements><Endothelial Cells><Endothelium><Engineering><Epithelial><Epithelial Cells><Epitheliasin Gene><Esteroproteases><Functional disorder><Genetic><HPGF><Hepatocyte-Stimulating Factor><Host Defense><Human><Hybridoma Growth Factor><Hydrops><IFN-beta 2><IFNB2><IL-1 beta><IL-1 β><IL-1-b><IL-1ra><IL-1β><IL-6><IL1 febrile inhibitor><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1RN><IL1β><IL6 Protein><Immune><Immune Mediators><Immune Mediators/Modulators><Immune Regulators><Immune response><Immune system><Immunes><Immunological response><Inflammasome><Inflammatory><Inflammatory Response><Injury><Interferon Type I><Interleukin 1beta><Interleukin-1 Receptor Antagonist><Interleukin-1 beta><Interleukin-1β><Interleukin-6><Intracellular Communication and Signaling><Intravenous><K-18><K-18 conjugate><K18><K18 combination><Knowledge><Ligand Binding Protein><Ligand Binding Protein Gene><Liquid substance><Lung><Lung Respiratory System><Lung damage><MGI-2><Mediating><Mice><Mice Mammals><Modern Man><Molecular Interaction><Murine><Mus><Myeloid Differentiation-Inducing Protein><Nature><PRSS10><Pathogenicity><Patients><Peptidases><Peptide Hydrolases><Peptides><Permeability><Pharmacology><Phase><Physiopathology><Plasmacytoma Growth Factor><Preinterleukin 1 Beta><Protease Gene><Proteases><Protein Binding><Proteinases><Proteins><Proteolytic Enzymes><Receptor Protein><Research><Role><Route><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 disease severity><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 severity><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Shock Lung><Signal Transduction><Signal Transduction Systems><Signaling><Stiff lung><Syndrome><TMPRSS2><TMPRSS2 gene><Testing><Therapeutic><Therapeutic Intervention><Tissues><Treatment Efficacy><United States><VE-Cadherin><Vaccination><Vaccines><Variant><Variation><Vascular Endothelial Cadherin><Vascular Endothelial Cadherin 1><Vascular Permeabilities><Viral><Viral Antigens><Virus><Wuhan coronavirus><access to vaccination><access to vaccines><allergic/immunologic body system><allergic/immunologic organ system><anakinra><angiotensin converting enzyme 2><angiotensin converting enzyme II><antagonist><base><biological signal transduction><bound protein><cadherin 5><cell damage><cell engineering><cell injury><cell type><cellular damage><cellular engineering><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 disease severity><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 severity><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease severity><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><critical injury><cytokine><cytokine release syndrome><cytokine storm><damage to cells><devastating injury><developmental><endothelial regeneration><fluid><hCoV19><host response><humanized mice><humanized mouse><immune system response><immunomodulatory biologics><immunoresponse><injuries><injury to cells><injury to tissue><interferon beta 2><interleukin 1 receptor antagonist protein><intervention efficacy><intervention therapy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><liquid><lung injury><lung vascular injury><mortality><mouse model><murine model><nCoV2><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pathophysiology><prevent><preventing><pulmonary><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><pulmonary vascular injury><receptor><response><scRNA-seq><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 disease severity><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 severity><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe injury><severe severe acute respiratory syndrome coronavirus 2><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><social role><therapeutic efficacy><therapeutic target><therapy efficacy><tissue injury><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><uptake><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><vaccination access><vaccination availability><vaccine access><vaccine availability><vaccine response><vaccine responsiveness><vaccine-induced response><variants of concern><vascular><virus antigen><wet lung>